Table of Contents

• Clinical trials overview
• Multiple sclerosis studies
• Other conditions studied
• Trial phases and designs
• Key endpoints measured in the trials
• Who the trials include
• What these trials mean for patients

Clinical trials overview

The trial data show that Interferon Beta-1A is being studied mainly in multiple sclerosis (MS), especially relapsing-remitting MS and other progressive forms of MS.^{[1][2][3][4][5]} These studies look at whether treatment can reduce disease activity, slow disability, and improve patient outcomes over time.^[1][3][4]

Multiple sclerosis studies

Several trials include relapsing-remitting multiple sclerosis (RRMS), which is a form of MS where symptoms worsen in attacks and then improve or settle down.^[2][4] One Phase 3 study in newly diagnosed RRMS patients compares ofatumumab with first-line disease-modifying treatments chosen by the physician, and Interferon Beta-1A is one of the treatments listed in the study options.^[2] The main outcome in that study is NEDA-3, which means no clinical relapses, no new MRI activity, and no confirmed worsening of disability.^[2]

Another Phase 3 study in older people with stable RRMS looks at whether treatment can be stopped without causing more disease activity.^[3] This study includes several MS disease-modifying therapies, including Interferon Beta-1A, and follows patients for 2 years.^[3] The trial measures the time to first clinical or radiological disease activity, which means the first sign of a relapse or a change seen on MRI.^[3]

A separate Phase 3 study focuses on people with inactive secondary progressive MS who are older than 50 years.^[4] In this trial, Interferon Beta-1A is among the therapies being withdrawn or continued, and the study compares treatment continuation with treatment withdrawal.^[4] The main endpoint is disability progression confirmed at 6 months, which means a lasting worsening in function measured on the EDSS scale.^[4]

There is also a Phase 3 pediatric RRMS study of BIIB017, described as peginterferon beta-1a, which evaluates safety, tolerability, efficacy, and pharmacokinetics in children and adolescents with RRMS.^[5] The study measures annualized relapse rate at Week 48 and later tracks adverse events and long-term outcomes.^[5]

One Phase 2 study in progressive MS is designed to test whether add-on treatment can delay disease progression compared with placebo.^[1] Although the main study drug is metformin, the treatment list includes Betaferon, AVONEX, Plegridy, Rebif, and other MS therapies, showing that Interferon Beta-1A-related products are part of the treatment background in this progressive MS research setting.^[1] The key outcome is change in walking speed measured by the T25FW test over 96 weeks.^[1]

Other conditions studied

Not all trials are in MS. One Phase 2 study in EBV-positive nasopharyngeal carcinoma includes Interferon Beta-1A in the treatment list together with nivolumab, cisplatin, 5-fluorouracil, and other drugs.^[6] The study includes children, adolescents, and young adults up to 25 years with locoregional disease, and it measures complete remission rate on MRI and PET/CT after induction treatment.^[6]

Another Phase 2 respiratory virus study uses a placebo matched to Interferon Beta-1A for inhalation.^[7] This trial is in mechanically ventilated patients with confirmed respiratory virus infection and measures safety first, then all-cause mortality within 28 days.^[7]

Trial phases and designs

The listed studies are mainly Phase 3 and Phase 2 trials.^{[1][2][3][4][5][1][6][7]} Phase 3 studies usually compare treatments in larger groups, while Phase 2 studies often focus on early signals of benefit, safety, and how the treatment performs in a smaller group.^{[1][2][1][6][7]}

Several studies use a randomized design, which means people are assigned by chance to different treatment groups.^[1][3][4] Some are open-label, meaning both the research team and the patient know which treatment is being given, while others are placebo-controlled or triple-blind, meaning the treatment assignment is hidden to reduce bias.^[1][3]

Key endpoints measured in the trials

The main study outcomes focus on how MS changes over time.^{[1][2][3][4][5][1]} These include walking speed measured by the T25FW test, which checks how fast a person can walk 25 feet.^[1] They also include relapse rate, MRI changes, disability worsening, and whether a patient has no disease activity at all.^[2][3][4][5]

In the RRMS studies, the endpoints include annualized relapse rate and NEDA-3 status, which combines relapse, MRI, and disability measures into one result.^[2][5] In the older MS withdrawal studies, the endpoint is time to first disease activity or confirmed disability progression.^[3][4] In the cancer study, the endpoint is complete remission rate, which means the share of patients who have a complete response on imaging tests.^[6]

Safety is also important in several trials.^[5][7] The pediatric RRMS study tracks adverse events, serious adverse events, and treatment discontinuation because of side effects.^[5] The respiratory virus study also measures adverse events and serious adverse events, including breathing and heart-related worsening.^[7]

Who the trials include

The target populations are quite different across studies.^{[2][3][4][5][6][7]} Some trials include newly diagnosed, treatment-naïve adults with RRMS, meaning they have not yet received MS disease-modifying treatment.^[2] Others focus on older adults with stable or inactive MS, where the goal is to see whether treatment can be safely continued or stopped.^[3][4]

The pediatric study includes children with RRMS, which is important because younger patients may respond differently and need long-term follow-up.^[5] The cancer study includes children, adolescents, and young adults up to age 25 with EBV-positive nasopharyngeal carcinoma.^[6] The respiratory virus trial includes mechanically ventilated patients with confirmed infection, which is a very different and much more acute patient group.^[7]

What these trials mean for patients

Overall, the trial data show that Interferon Beta-1A is being studied mostly as part of MS treatment research, especially in people with relapsing forms of the disease.^[2][3][4][5] The studies are trying to understand whether treatment helps prevent relapses, reduce MRI activity, slow disability, or support safe treatment changes over time.^{[1][2][3][4][5]}

Some trials do not test Interferon Beta-1A as the main study drug, but they still include it as a comparator, background therapy, or placebo match.^[1][6][7] This means the research is not only about whether the treatment works, but also about where it fits in modern treatment strategies for different patient groups.^[2][3][4]